Eukaryotic elongation factor 2 controls TNF-α translation in LPS-induced hepatitis

Journal of Clinical Investigation

Volumn 123, Issue 1, 2013, Pages 164-178

  González Terán, Bárbara ^a   Cortés, José R ^a   Manieri, Elisa ^a,b   Matesanz, Nuria ^a   Verdugo, Ángeles ^a,b   Rodríguez, María E ^a   González Rodríguez, Águeda ^c,d   Valverde, Ángela ^c,d   Martín, Pilar ^a   Davis, Roger J ^e   Sabio, Guadalupe ^a  

^a CENTRO NACIONAL DE INVESTIGACIONES CARDIOVASCULARES CNIC   (Spain)

^b CENTRO NACIONAL DE BIOTECNOLOGÍA   (Spain)

^c INSTITUTO DE INVESTIGACIONES BIOMÉDICAS ALBERTO SOLS   (Spain)

^d INSTITUTO DE SALUD CARLOS III   (Spain)

^e UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ELONGATION FACTOR 2; ENDOTOXIN; EUKARYOTIC ELONGATION FACTOR 2; INTERLEUKIN 6; LENTIVIRUS VECTOR; MITOGEN ACTIVATED PROTEIN KINASE KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE KINASE 6; MITOGEN ACTIVATED PROTEIN KINASE P38; SHORT HAIRPIN RNA; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BONE MARROW CELL; CELL INFILTRATION; CELL MIGRATION; CELL POPULATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; ENZYME PHOSPHORYLATION; GENE SILENCING; GENETIC TRANSCRIPTION; HEMATOPOIETIC CELL; HEPATITIS; IMMUNOPRECIPITATION; KUPFFER CELL; LENTIVIRINAE; LEUKOCYTE; LIVER CELL; LIVER INJURY; LIVER PROTECTION; MACROPHAGE; MOUSE; NEUTROPHIL; NEUTROPHIL CHEMOTAXIS; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN DEPHOSPHORYLATION; PROTEIN EXPRESSION; RNA TRANSLATION; SIGNAL TRANSDUCTION; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY;

ANIMALS; DISEASE MODELS, ANIMAL; DRUG-INDUCED LIVER INJURY; GENE EXPRESSION REGULATION; HEK293 CELLS; HUMANS; LIPOPOLYSACCHARIDES; MACROPHAGES; MAP KINASE KINASE 3; MAP KINASE KINASE 6; MAP KINASE SIGNALING SYSTEM; MICE; MICE, KNOCKOUT; MITOGEN-ACTIVATED PROTEIN KINASE 12; MITOGEN-ACTIVATED PROTEIN KINASE 13; PEPTIDE CHAIN ELONGATION, TRANSLATIONAL; PEPTIDE ELONGATION FACTOR 2; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84873810502     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI65124     Document Type: Article

References (57)

1. Kim C, et al. The kinase p38 alpha serves cell typespecific inflammatory functions in skin injury and coordinates pro- and anti-inflammatory gene expression. Nat Immunol. 2008;9(9): 1019-1027.
2. Wu Z, Han M, Chen T, Yan W, Ning Q. Acute liver failure: mechanisms of immune-mediated liver injury. Liver Int. 2010;30(6): 782-794.
3. Antoniades CG, Berry PA, Wendon JA, Vergani D. The importance of immune dysfunction in determining outcome in acute liver failure. J Hepatol. 2008;49(5): 845-861.
4. Popa C, Netea MG, van Riel PL, van der Meer JW, Stalenhoef AF. The role of TNF-alpha in chronic inflammatory conditions, intermediary metabolism, and cardiovascular risk. J Lipid Res. 2007;48(4): 751-762.
5. Wajant H, Pfizenmaier K, Scheurich P. Tumor necrosis factor signaling. Cell Death Differ. 2003;10(1): 45-65.
6. Bradley Jr. TNF-mediated inflammatory disease. J Pathol. 2008;214(2): 149-160.
7. Schwabe RF, Brenner DA. Mechanisms of Liver Injury. I. TNF-alpha-induced liver injury: role of IKK, JNK, and ROS pathways. Am J Physiol Gastrointest Liver Physiol. 2006;290:G583-G589.
8. Pfeffer KD, Huecksteadt TP, Hoidal Jr. Expression and regulation of tumor necrosis factor in macrophages from cystic fibrosis patients. Am J Respir Cell Mol Biol. 1993;9(5): 511-519.
9. Pasparakis M, Alexopoulou L, Douni E, Kollias G. Tumour necrosis factors in immune regulation: everything that's interesting is...new! Cytokine Growth Factor Rev. 1996;7(3): 223-229.
10. Nebreda AR, Porras A. p38 MAP kinases: beyond the stress response. Trends Biochem Sci. 2000; 25(6): 257-260.
11. Schieven GL. The biology of p38 kinase: a central role in inflammation. Curr Top Med Chem. 2005;5(10): 921-928.
12. Cuenda A, Rousseau S. p38 MAP-kinases pathway regulation, function and role in human diseases. Biochim Biophys Acta. 2007;1773(8): 1358-1375.
13. Kyriakis JM, Avruch J. Mammalian mitogen-activated protein kinase signal transduction pathways activated by stress and inflammation. Physiol Rev. 2001;81(2): 807-869.
14. Brancho D, et al. Mechanism of p38 MAP kinase activation in vivo. Genes Dev. 2003;17(16): 1969-1978.
15. Remy G, et al. Differential activation of p38 MAPK isoforms by MKK6 and MKK3. Cell Signal. 2010;22(4): 660-667.
16. Heinrichsdorff J, Luedde T, Perdiguero E, Nebreda AR, Pasparakis M. p38 alpha MAPK inhibits JNK activation and collaborates with IkappaB kinase 2 to prevent endotoxin-induced liver failure. EMBO Rep. 2008;9(10): 1048-1054.
17. Hui L, et al. p38alpha suppresses normal and cancer cell proliferation by antagonizing the JNK-c-Jun pathway. Nat Genet. 2007;39(6): 741-749.
18. Beardmore VA, et al. Generation and characterization of p38beta (MAPK11) gene-targeted mice. Mol Cell Biol. 2005;25(23): 10454-10464.
19. Knebel A, Morrice N, Cohen P. A novel method to identify protein kinase substrates: eEF2 kinase is phosphorylated and inhibited by SAPK4/p38delta. EMBO J. 2001;20(16): 4360-4369.
20. Jung GA, et al. Methylation of eukaryotic elongation factor 2 induced by basic fibroblast growth factor via mitogen-activated protein kinase. Exp Mol Med. 2011;43(10): 550-560.
21. Browne GJ, Proud CG. Regulation of peptide-chain elongation in mammalian cells. Eur J Biochem. 2002;269(22): 5360-5368.
22. Wang L, Wang X, Proud CG. Activation of mRNA translation in rat cardiac myocytes by insulin involves multiple rapamycin-sensitive steps. Am J Physiol Heart Circ Physiol. 2000;278(4):H1056-H1068.
23. Knebel A, Haydon CE, Morrice N, Cohen P. Stressinduced regulation of eukaryotic elongation factor 2 kinase by SB 203580-sensitive and -insensitive pathways. Biochem J. 2002;367(pt 2): 525-532.
24. Ono K, Han J. The p38 signal transduction pathway: activation and function. Cell Signal. 2000;12(1): 1-13.
25. Mahtani KR, Brook M, Dean JL, Sully G, Saklatvala J, Clark AR. Mitogen-activated protein kinase p38 controls the expression and posttranslational modification of tristetraprolin, a regulator of tumor necrosis factor alpha mRNA stability. Mol Cell Biol. 2001;21(19): 6461-6469.
26. Turpeinen T, Nieminen R, Moilanen E, Korhonen R. Mitogen-activated protein kinase phosphatase-1 negatively regulates the expression of interleukin- 6, interleukin-8, and cyclooxygenase-2 in A549 human lung epithelial cells. J Pharmacol Exp Ther. 2010;333(1): 310-318.
27. Nagaleekar VK, et al. Translational control of NKT cell cytokine production by p38 MAPK. J Immunol. 2011;186(7): 4140-4146.
28. Kotlyarov A, et al. MAPKAP kinase 2 is essential for LPS-induced TNF-alpha biosynthesis. Nat Cell Biol. 1999;1(2): 94-97.
29. Ramaiah SK, Jaeschke H. Role of neutrophils in the pathogenesis of acute inflammatory liver injury. Toxicol Pathol. 2007;35(6): 757-766.
30. Alagbala Ajibade A, et al. TAK1 negatively regulates NF-kappaB and p38 MAP kinase activation in Gr-1(+)CD11b(+) neutrophils. Immunity. 2012;36(1): 43-54.
31. Xia S, Sha H, Yang L, Ji Y, Ostrand-Rosenberg S, Qi L. Gr-1+ CD11b+ myeloid-derived suppressor cells suppress inflammation and promote insulin sensitivity in obesity. J Biol Chem. 2011;286(26): 23591-23599.
32. Dong Z, Wei H, Sun R, Tian Z. The roles of innate immune cells in liver injury and regeneration. Cell Mol Immunol. 2007;4(4): 241-252.
33. Kuma Y, Sabio G, Bain J, Shpiro N, Marquez R, Cuenda A. BIRB796 inhibits all p38 MAPK isoforms in vitro and in vivo. J Biol Chem. 2005;280(20): 19472-19479.
34. Cuenda A, et al. SB 203580 is a specific inhibitor of a MAP kinase homologue which is stimulated by cellular stresses and interleukin-1. FEBS Lett. 1995;364(2): 229-233.
35. Clausen BE, Burkhardt C, Reith W, Renkawitz R, Forster I. Conditional gene targeting in macrophages and granulocytes using LysMcre mice. Transgenic Res. 1999;8(4): 265-277.
36. Sabio G, et al. Stress- and mitogen-induced phosphorylation of the synapse-associated protein SAP90/PSD-95 by activation of SAPK3/p38gamma and ERK1/ERK2. Biochem J. 2004;380(pt 1): 19-30.
37. Sabio G, et al. p38gamma regulates the localisation of SAP97 in the cytoskeleton by modulating its interaction with GKAP. EMBO J. 2005;24(6): 1134-1145.
38. Jonsson F, et al. Mouse and human neutrophils induce anaphylaxis. J Clin Invest. 2011;121(4): 1484-1496.
39. Kolios G, Valatas V, Kouroumalis E. Role of Kupffer cells in the pathogenesis of liver disease. World J Gastroenterol. 2006;12(46): 7413-7420.
40. Noubade R, et al. Activation of p38 MAPK in CD4 T cells controls IL-17 production and autoimmune encephalomyelitis. Blood. 2011;118(12): 3290-3300.
41. Kotlyarov A, Gaestel M. Is MK2 (mitogen-activated protein kinase-activated protein kinase 2) the key for understanding post-transcriptional regulation of gene expression? Biochem Soc Trans. 2002;30(pt 6): 959-963.
42. Shi C, et al. Bone marrow mesenchymal stem and progenitor cells induce monocyte emigration in response to circulating toll-like receptor ligands. Immunity. 2011;34(4): 590-601.
43. Lee JC, et al. A protein kinase involved in the regulation of inflammatory cytokine biosynthesis. Nature. 1994;372(6508): 739-746.
44. Kang YJ, et al. Macrophage deletion of p38alpha partially impairs lipopolysaccharide-induced cellular activation. J Immunol. 2008;180(7): 5075-5082.
45. Lee MR, Dominguez C. MAP kinase p38 inhibitors: clinical results and an intimate look at their interactions with p38alpha protein. Curr Med Chem. 2005;12(25): 2979-2994.
46. Schreiber S, et al. Oral p38 mitogen-activated protein kinase inhibition with BIRB 796 for active Crohn's disease: a randomized, double-blind, placebo-controlled trial. Clin Gastroenterol Hepatol. 2006;4(3): 325-334.
47. Wysk M, Yang DD, Lu HT, Flavell RA, Davis RJ. Requirement of mitogen-activated protein kinase kinase 3 (MKK3) for tumor necrosis factor-induced cytokine expression. Proc Natl Acad Sci U S A. 1999;96(7): 3763-3768.
48. Lu HT, et al. Defective IL-12 production in mitogenactivated protein (MAP) kinase kinase 3 (Mkk3)- deficient mice. EMBO J. 1999;18(7): 1845-1857.
49. Tanaka N, et al. Differential involvement of p38 mitogen-activated protein kinase kinases MKK3 and MKK6 in T-cell apoptosis. EMBO Rep. 2002;3(8): 785-791.
50. Chopra P, et al. Pharmacological profile of AW-814141, a novel, potent, selective and orally active inhibitor of p38 MAP kinase. Int Immunopharmacol. 2010;10(4): 467-473.
51. Sukhtankar D, et al. Inhibition of p38-MAPK signaling pathway attenuates breast cancer induced bone pain and disease progression in a murine model of cancer-induced bone pain. Mol Pain. 2011;7:81.
52. Urso K, et al. NFATc3 regulates the transcription of genes involved in T-cell activation and angiogenesis. Blood. 2011;118(3): 795-803.
53. Kim L, Butcher BA, Denkers EY. Toxoplasma gondii interferes with lipopolysaccharide-induced mitogen-activated protein kinase activation by mechanisms distinct from endotoxin tolerance. J Immunol. 2004;172(5): 3003-3010.
54. Kuboki S, et al. Hepatocyte NF-kappaB activation is hepatoprotective during ischemia-reperfusion injury and is augmented by ischemic hypothermia. Am J Physiol Gastrointest Liver Physiol. 2007;292(1):G201-G207.
55. Partida-Sanchez S, et al. Chemotaxis of mouse bone marrow neutrophils and dendritic cells is controlled by adp-ribose, the major product generated by the CD38 enzyme reaction. J Immunol. 2007;179(11): 7827-7839.
56. Mayoral R, Valverde AM, Llorente Izquierdo C, Gonzalez- Rodriguez A, Bosca L, Martin-Sanz P. Impairment of transforming growth factor beta signaling in caveolin-1-deficient hepatocytes: role in liver regeneration. J Biol Chem. 2010;285(6): 3633-3642.
57. Cruz-Adalia A, et al. CD69 limits the severity of cardiomyopathy after autoimmune myocarditis. Circulation. 2010;122(14): 1396-1404.